Evaluating response to radium-223 using
PSMA PET/CT
Prognosis
Prostate cancer
Radium-223
Response
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
23
08
2024
accepted:
30
09
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
aheadofprint
Résumé
Conventional imaging techniques and prostate-specific antigen (PSA) values are not useful to follow-up patients during Radium-223 treatment. The study aimed to evaluate the predictive value of prostate-specific membrane antigen PSMA PET/CT-based response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Radium-223 dichloride treatment. Patients treated with radium-223, having performed two Twenty-eight mCRPC patients were evaluated. Sixteen (43%) and 18 (64%) patients had PD according to RECIP1.0 and PPP, respectively; κ = 0.85 (95% CI 0.65-1.00). After a median follow-up of 16 months (interquartile IQR 9-33), 20 (71%) patients died. Patients with PSMA PD showed a higher risk of death than non-PD according to RECIP1.0 (HR = 2.9; 95% CI 1.14-7.46; p = 0.029) and PPP (HR = 2.8; 95% CI 1.04-7.64; p = 0.042). For both criteria, the median OS was shorter for PD than non-PD (37 vs. 12 months, Log-rank; p < 0.05). The C-index for RECIP1.0 and PPP were almost equal (0.66 and 0.63; respectively). This study demonstrated that PSMA-PET/CT imaging is valuable for monitoring radium-223 treatment. Both PSMA PET/CT response criteria (RECIP1.0 and PPP) perform similarly predicting OS at follow-up after three cycles of radium-223. These findings urge further validation in prospective trials.
Identifiants
pubmed: 39368051
doi: 10.1007/s12149-024-01990-w
pii: 10.1007/s12149-024-01990-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol. 2004;5:607–16.
doi: 10.1016/S1470-2045(04)01596-7
Terrisse S, Karamouza E, Parker CC, et al. Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: a meta-analysis of individual patient data from randomized clinical trials. JAMA Oncol. 2020;6:206–16.
doi: 10.1001/jamaoncol.2019.4097
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
doi: 10.1056/NEJMoa1213755
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42.
doi: 10.1016/j.eururo.2016.08.002
Morris MJ, Corey E, Guise TA, et al. Radium-223 mechanism of action: implications for use in treatment combinations. Nat Rev Urol. 2019;16:745–56.
doi: 10.1038/s41585-019-0251-x
pmcid: 7515774
Keizman D, Fosboel MO, Reichegger H, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. Prostate Cancer Prostatic Dis. 2017;20:289–93.
doi: 10.1038/pcan.2017.6
Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working Group 3. J Clin Oncol. 2016;34:1402–18.
doi: 10.1200/JCO.2015.64.2702
pmcid: 4872347
Sartor O, Coleman RE, Nilsson S, et al. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223. Ann Oncol. 2017;28:1090–7.
doi: 10.1093/annonc/mdx044
pmcid: 5406754
Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:2114–21.
doi: 10.1007/s00259-016-3435-0
Gafita A, Rauscher I, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63:1651–8.
pmcid: 9635677
Shagera QA, Artigas C, Karfis I, et al. (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy. J Nucl Med. 2022;63:1191–8.
doi: 10.2967/jnumed.121.263006
Denis CS, Cousin F, Laere B, Hustinx R, Sautois BR, Withofs N. Using 68Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: application of EAU/EANM recommendations in clinical practice. J Nucl Med. 2022;63:1815–21.
doi: 10.2967/jnumed.121.263611
pmcid: 9730923
Rosar F, Wenner F, Khreish F, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in 68Ga-PSMA-11 PET/CT independently predicts overall survival in 177Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49:1584–94.
doi: 10.1007/s00259-021-05594-8
Plouznikoff N, Artigas C, Sideris S, et al. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Ann Nucl Med. 2019;33:945–54.
doi: 10.1007/s12149-019-01404-2
Shagera QA, Karfis I, Kristanto P, et al. PSMA PET/CT for response assessment and overall survival prediction in patients with metastatic castration-resistant prostate cancer treated with androgen receptor pathway inhibitors. J Nucl Med. 2023;64:1869–75.
doi: 10.2967/jnumed.123.265874
Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria. J Nucl Med. 2020;61:678–82.
doi: 10.2967/jnumed.119.233817
pmcid: 7198387
Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing response to [(177)Lu]PSMA radioligand therapy using modified PSMA PET progression criteria. J Nucl Med. 2021;62:1741–6.
doi: 10.2967/jnumed.120.260836
pmcid: 8612188
Lunger L, Chantadisai M, Karimzadeh A, et al. The prognostic role of 68Ga-PSMA11 PET-based response in prostate cancer patients undergoing taxane-based chemotherapy. J Nucl Med. 2023;64:896–901.
doi: 10.2967/jnumed.122.264962
Fanti S, Goffin K, Hadaschik BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:469–76.
doi: 10.1007/s00259-020-04934-4
Gafita A, Rauscher I, Fendler WP, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49:4271–81.
doi: 10.1007/s00259-022-05882-x
Seifert R, Emmett L, Rowe SP, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405–12.
doi: 10.1016/j.eururo.2023.02.002
Gafita A, Bieth M, Krönke M, et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET/CT. J Nucl Med. 2019;60:1277–83.
doi: 10.2967/jnumed.118.224055
pmcid: 6735278
R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ .
Antolini L, Boracchi P, Biganzoli E. A time-dependent discrimination index for survival data. Stat Med. 2005;24:3927–44.
doi: 10.1002/sim.2427
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.
doi: 10.1016/S0140-6736(20)30314-7
García Vicente AM, Amo-Salas M, Cassinello Espinosa J, Gómez Díaz R, Soriano CÁ. Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride. Sci Rep. 2021;11:7389.
doi: 10.1038/s41598-021-86759-1
pmcid: 8016973
Kairemo K, Joensuu T. Radium-223-dichloride in castration resistant metastatic prostate cancer-preliminary results of the response evaluation Using F-18-fluoride PET/CT. Diagnostics (Basel). 2015;5:413–27.
doi: 10.3390/diagnostics5040413
Bénard F, Harsini S, Wilson D, et al. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial. Lancet Oncol. 2022;23:1499–507.
doi: 10.1016/S1470-2045(22)00642-8
Sheikhbahaei S, Jones KM, Werner RA, et al. 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Ann Nucl Med. 2019;33:351–61.
doi: 10.1007/s12149-019-01343-y
Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–7.
doi: 10.1016/j.ejca.2016.03.081
pmcid: 5737828
Ceci F, Oprea-Lager DE, Emmett L, et al. E-PSMA: the EANM standardized reporting guidelines v10 for PSMA-PET. Eur J Nucl Med Mol Imaging. 2021;48:1626–38.
doi: 10.1007/s00259-021-05245-y
pmcid: 8113168
Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78.
doi: 10.2967/jnumed.117.198119